Boundless Bio, Inc. BOLD 深 滬
等待開盤 08-14 09:30:00 美东时间
1.17
+0.050
+4.46%
華盛通- 最 高1.185
- 今 開1.14
- 成交量 9.05万股
- 最 低 1.14
- 昨 收 1.12
- 總市值 2619.12万
- 52周最高 4.72
- 市盈率 靜 --
- 換手率 0.40%
- 52周最低 1.00
- 委 比 -93.93%
- 總股本 2238.56万
- 歷史最高 15.24
- 量 比 1.66
- 振 幅 4.02%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.
08-11 18:43
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
08-05 11:00
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
08-05 01:38
重新审视稳定币的三难困境：当前去中心化的衰落
文章来源：Odaily星球日报 原文作者：Chilla 原文编译：Block unicorn 前言 稳定币备受关注，这并非无故。它除了投机之...
06-30 20:00
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, announced that President and CEO Zachary Hornby will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL. The session will be live and archived on the company’s Investor Relations website. Boundless Bio is developing ecDNA-directed therapeutic candidates to address ...
06-05 20:58
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3
Leerink Partners analyst Michael Cherny downgrades Boundless Bio (NASDAQ:BOLD) from Outperform to Market Perform and lowers the price target from $15 to $3.
05-28 23:53
Boundless Bio Q1 EPS $(0.71) Beats $(0.73) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.73) by 2.74 percent. This is a 94.21 percent increase over losses of $(12.27) per share from the
05-09 19:19
Praxis Precision Medicines Shares Promising EMBOLD Study Data
An update from Praxis Precision Medicines ( ($PRAX) ) is now available. On May ...
05-03 05:28
